| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 795-797 |
| Número de páginas | 3 |
| Publicación | American Heart Journal |
| Volumen | 162 |
| N.º | 5 |
| DOI | |
| Estado | Published - nov 2011 |
Nota bibliográfica
Funding Information:Dr. Aguilar has received consulting fees from Amylin and Sanofi-Aventis. Dr Aguilar is a research investigator in the ELIXA trial and EXSCEL trial and is supported by an NHLBI Mentored Career Development award ( 5K01-HL092585-03 ).
Financiación
Dr. Aguilar has received consulting fees from Amylin and Sanofi-Aventis. Dr Aguilar is a research investigator in the ELIXA trial and EXSCEL trial and is supported by an NHLBI Mentored Career Development award ( 5K01-HL092585-03 ).
| Financiadores | Número del financiador |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | K01HL092585 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Huella
Profundice en los temas de investigación de 'Heart failure and diabetes: Time to pay attention'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver